White adipose tissue‐derived small extracellular vesicles: A new potential therapeutic reagent for accelerating diabetic wound healing

Abstract

Small extracellular vesicles (sEVs) from adipose‐derived stem cells (ADSCs) have gained great attention and have been widely used in cell‐free therapies for treating diabetic non‐healing wounds in recent years. However, further clinical application of ADSC‐sEVs have been limited due to their unsolvable defects, including cumbersome extraction procedure, high cost, low yield, etc. Thus, we urgently need to find one therapeutic reagent that could not only accelerate diabetic wound healing as ADSC‐sEVs but also overcome these shortcomings. As the extraction process of adipose tissue‐derived sEVs (AT‐sEVs) is quite simple and labor saving, we put our focus on the efficiencies of white adipose tissue‐derived sEVs (WAT‐sEVs) and brown adipose tissue‐derived sEVs (BAT‐sEVs) in diabetic wound repair. After successfully isolating WAT‐sEVs and BAT‐sEVs by ultracentrifugation, we thoroughly characterized them and compared their diabetic wound healing capabilities both in vitro and in vivo. According to our study, AT‐sEVs possess similar competence in diabetic wound healing as compared with ADSC‐sEVs. While the effect of BAT‐sEVs is not as stable as WAT‐sEVs and ADSC‐sEVs, the repair efficiency is also slightly lower than the other two sEVs in some cases. In summary, we are the first to discover that WAT‐sEVs show great potential in diabetic wound repair. With advantages that are specific to tissue‐derived sEVs (Ti‐sEVs) such as time‐ and cost‐saving, high‐yield, and simple isolation procedure, we believe WAT‐sEVs could serve as a novel reliable cell‐free therapy for clinical diabetic wound treatment.